Connect Biopharma Holdings Limited · NASDAQ:CNTB
Connect Biopharma — Technical Presentation (May 2022)
14 slides from Connect Biopharma's technical presentation, May 3, 2022
Slide 1: CBP-307 Top-line Phase 2 Results in Ulcerative Colitis
CBP-307 Top-line Phase 2 Results in Ulcerative Colitis Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation regarding Connect Biopharma Holdings Limited ("Connect," "we," "us" or "our") has been prepared solely for informational purposes. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data
Slide 3: Large opportunity where high unmet need remains despite treatment advances
2 Large opportunity where high unmet need remains despite treatment advances An autoimmune disease that causes inflammation and ulceration of the inner lining of the colon and rectum (the large bowel) Ulcerative Colitis (UC) Majority of IBD patients in the US had UC 4 6.8 M IBD patients worldwide in
Slide 4: CBP-307: Potential for Differentiation
CBP-307: Potential for Differentiation CBP-307 has molecular design features that offer potential for differentiation Next-generation S1P1 modulators that are approved or have demonstrated positive proof-of-concept* in T-cell driven diseases include ozanimod (MS, IBD) and etrasimod (AD, UC) CBP-307
Slide 5: CBP-307CN002 Trial: Phase 2 Study Design in Moderate-to-Severe UC
Primary and all secondary endpoints were assessed at Week 12 in the induction phase CBP-307CN002 Trial: Phase 2 Study Design in Moderate-to-Severe UC Response Assessed STAGE 1 INDUCTION PHASE (12-WEEK) Placebo (n=53) Screen Randomized (n=145 1:1:1)* CBP-307 (n=53) 0.2 mg PO QD* CBP-307 (n=39)* 0.1 m
Slide 6: Demographics & Characteristics
Demographics & Characteristics CBP-307 0.1 mg PO QD (n=39) CBP-307 0.2 mg PO QD (n=53) Placebo (n=53) Mean age, years (SD) 42.9 (13.4) 42.1 (10.7) 42.2 (9.9) Female, n (%) 14 ( 35.9) 20 (37.7) 20 (37.7) Race, n (%) White Asian Black/African American Not reported 0 39 (100.0) 0 0 5 (9.4) 48 (90.6) 0
Slide 7: CBP-307CN002 Trial - Primary and Secondary Efficacy Endpoints
FAS, full analysis set; MI, multiple imputation; PO, by mouth; QD, once daily. Placebo-adjusted data is the difference in score between CBP-307 and placebo. CBP-307CN002 Trial - Primary and Secondary Efficacy Endpoints Change from baseline in Adapted and Complete Mayo score at W12 compared between C
Slide 8: Secondary Efficacy Endpoints at Week 12: Clinical Remission
CBP-307CN002 Trial – Secondary Efficacy Endpoints at Week 12 Clinical Remission based on Adapted and Complete Mayo scores FAS, full analysis set; NRI, non-responder imputation; PO, by mouth; QD, once daily. Adapted Mayo scores exclude PGA (Physician’s Global Assessment) score Clinical remission rate
Slide 9: Secondary Efficacy Endpoints at Week 12: Clinical Response
CBP-307CN002 Trial - Secondary Efficacy Endpoints at Week 12 Clinical Response based on Adapted and Complete Mayo scores FAS, full analysis set; NRI, non-responder imputation; PO, by mouth; QD, once daily. Adapted Mayo scores exclude PGA score Clinical Response rate at Week 12 (FAS, NRI) based on co
Slide 10: Secondary Endpoints: Clinical Remission Rate Comparison
Δ = 3.5% (p = 0.601) CBP-307CN002 - Secondary Endpoints Clinical Remission rate based on Adapted and Complete Mayo score 1. Sandborn et al. Gastroenterology. 2020;158:550–561 and Seeking Alpha article (“Arena Jumps On Positive Clinical Trial Results”, March 20, 2018) & Arena Pharmaceuticals. 2. Sand
Slide 11: Secondary Endpoints: Clinical Response Rate at Week 12
Δ = 18.9% (p < 0.03) Δ = 11.4% (p = 0.13) CBP-307CN002 - Secondary Endpoints Clinical response rate at Week 12, based on Adapted and Complete Mayo * Mayo decrease of ≥2 points and ≥30%, and a decrease of ≥1 in RB or an absolute RB ≤1 ** Mayo decrease of ≥3 points and ≥30%, and a decrease ≥1 in RB or
Slide 12: Pharmacodynamic Endpoint: Peripheral Lymphocyte Counts
CBP-307 reduced the peripheral lymphocyte counts during the 12-week study period CBP-307CN002 Trial - Pharmacodynamic Endpoint Absolute lymphocyte counts (ALC) and percentage change through Week 12 (FAS) Mean values and Percentage changes in Absolute Lymphocyte Count (ALC) 1.0 0.8 0.5 0.2
Slide 13: Safety Results from 12-week Induction Period
Overall TEAEs, including drug-related TEAEs and TEAEs of special interest, were more frequent in the CBP-307 groups Most TEAEs were mild and moderate in severity CBP-307 0.2 mg QD showed similar frequencies of SAEs and TEAEs leading to study drug withdrawal as placebo No cases of progressive multifo
Slide 14: Summary: Conclusions from 12 Week Induction Period
CBP-307 0.2 mg PO QD decreased disease severity based on adapted Mayo Score after 12 weeks of treatment, although the change did not reach statistical significance CBP-307 0.2 mg PO QD achieved statistical significance on several secondary endpoints including for Clinical Remission Clear dose-depend
Connect Biopharma Holdings — Technical Presentation (May 2022) on 6ix